Skip to main content

PULSE BIOSCIENCES, INC.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

PLSE$55.12-5.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 15. Exhibits, Financial Statement Schedules

(a) The following documents are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K:

1.Financial Statements: See Item 8 of this Annual Report on Form 10-K.

2.Financial Statement Schedules: All schedules are omitted because they are not required, are not applicable or the information is included in the consolidated financial statements or notes thereto.

(b) The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K:

Exhibit · Incorporation by Reference
NumberExhibit DescriptionFormFile No.Exhibit(s)Filing Date
2.1Plan of Conversion of Pulse Biosciences, Inc.8-K12B001-377442.1June 18, 2018
3.1Articles of Conversion8-K12B001-377443.1June 18, 2018
3.2Certificate of Conversion8-K12B001-377443.2June 18, 2018
3.3Certificate of Incorporation of Pulse Biosciences, Inc.8-K12B001-377443.3June 18, 2018
3.4Bylaws of Pulse Biosciences, Inc.8-K12B001-377443.4June 18, 2018
4.1Specimen Common Stock Certificate8-K12B001-377444.1June 18, 2018
4.2Form of WarrantS-3333-2784944.3April 3, 2024
4.3Form of Warrant Agent AgreementS-3333-2784944.4April 3, 2024
10.1Lease for facilities at 3955 Point Eden Way, Hayward, California, dated January 26, 201710-K001-3774410.1March 20, 2017
10.2+Employment Agreement between Mitchell E. Levinson and the Registrant10-K001-3774410.4March 31, 2022
10.3+Employment Agreement between Kevin Danahy and the Registrant10-K001-3774410.5March 31, 2022
10.4+2015 Stock Incentive PlanS-1333-20869410.2December 22, 2015
10.5+2017 Inducement Equity Incentive Plan and forms of agreements thereunder8-K001-3774410.1November 28, 2017
10.6*2017 Equity Incentive Plan and forms of agreements thereunder
10.7+2017 Employee Stock Purchase Plan and forms of agreements thereunder8-K001-3774410.2May 19, 2017
10.8+Executive Employment Agreement between Darrin R. Uecker and the RegistrantS-1333-20869410.9December 22, 2015
10.9+Amendment to Employment Agreement between Darrin R. Uecker and Pulse Biosciences, Inc. dated October 5, 20168-K001-3774410.1October 11, 2016
10.10+Form of At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement for EmployeesS-1333-20869410.10December 22, 2015
10.11+Form of Indemnification Agreement8-K12B001-3774410.1June 18, 2018
10.12First Amendment to the lease for facilities at 3955 Point Eden Way, Hayward, California, dated May 28, 20198-K001-3774410.19May 31, 2019
10.13At-the-Market Equity Offering Sales Agreement8-K001-377441.1July 15, 2024
10.14Indemnification Letter, dated May 27, 2022, by and between Pulse Biosciences, Inc. and Robert W. Duggan10-Q001-3774410.1August 10, 2022
10.15Loan Agreement, dated as of September 20, 2022, by and between Pulse Biosciences, Inc. and Robert W. Duggan8-K001-3774410.1September 23, 2022
10.16+Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated September 20, 20228-K001-3774410.2September 23, 2022
10.17+Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated September 23, 20228-K001-3774410.1September 28, 2022
10.18+Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated May 4, 20238-K001-3774410.1May 5, 2023
10.19+Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated May 5, 20238-K001-3774410.2May 5, 2023
10.20+Third Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated March 26, 202410-K001-3774410.26March 28, 2024
10.21+Fourth Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated March 26, 202410-K001-3774410.27March 28, 2024
10.22+Employment Agreement between Paul A. LaViolette and Pulse Biosciences, Inc., dated January 9, 20258-K001-3774410.1January 13, 2025
10.23+Employment Agreement between Jon Skinner and Pulse Biosciences, Inc., dated January 31, 20258-K001-3774410.1January 31, 2025
14.1*Code of Business Conduct and Ethics
19.1*Insider Trading Policy of Pulse Biosciences, Inc. (as amended and restated on February 19, 2026)
21.1*List of Subsidiaries
23.1*Consent of Independent Registered Public Accounting Firm
31.1*Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
32.2*Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
97.1+Section 10D Clawback Policy10-K001-3774497.1March 28, 2024
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Filed herewith
+ Indicates a management contract or compensatory plan or arrangement.
# Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a grant of confidential treatment.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.